A molecular basis for selective antagonist destabilization of dopamine D3 receptor quaternary organization

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Marsango, Sara ^a,c   Caltabiano, Gianluigi ^b   Jiménez Rosés, Mireia ^b   Millan, Mark J ^c   Pediani, John D ^a   Ward, Richard J ^a   Milligan, Graeme ^a,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; PROTEIN BINDING; SPIPERONE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR DOCKING; PROTEIN MULTIMERIZATION;

DOPAMINE ANTAGONISTS; HALOPERIDOL; HEK293 CELLS; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, DOPAMINE D3; SPIPERONE;

EID: 85019903749     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-02249-3     Document Type: Article

References (56)

1. Rangel-Barajas, C., Coronel, I. & Florán, B. Dopamine Receptors and Neurodegeneration. Aging Dis. 6, 349-368, doi: 10.14336/AD.2015.0330 (2015).
2. Maggio, R., Scarselli, M., Capannolo, M. & Millan, M. J. Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation. Eur. Neuropsychopharmacol. 25, 1470-1479, doi: 10.1016/j.euroneuro.2014.09.016 (2015).
3. Beaulieu, J. M. & Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182-217, doi: 10.1124/pr.110.002642 (2011).
4. Ferré, S. et al. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol. Rev. 66, 413-434, doi: 10.1124/pr.113.008052 (2014).
5. Guo, W., Shi, L. & Javitch, J. A. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J. Biol. Chem. 278, 4385-4388, doi: 10.1074/jbc.C200679200 (2003).
6. Guo, W., Shi, L., Filizola, M., Weinstein, H. & Javitch, J. A. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc. Natl. Acad. Sci USA 102, 17495-17500, doi: 10.1073/pnas.0508950102 (2005).
7. Guo, W. et al. Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J. 27, 2293-2304, doi: 10.1038/emboj.2008.153 (2008).
8. Pou, C., la Cour, C. M., Stoddart, L. A., Millan, M. J. & Milligan, G. Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface. J. Biol. Chem. 287, 8864-8878, doi: 10.1074/jbc.M111.326678 (2012).
9. Aslanoglou, D., Alvarez-Curto, E., Marsango, S. & Milligan, G. Distinct Agonist Regulation of Muscarinic Acetylcholine M2-M3 Heteromers and Their Corresponding Homomers. J. Biol. Chem. 290, 14785-14796, doi: 10.1074/jbc.M115.649079 (2015).
10. Gorinski, N. et al. Computational and experimental analysis of the transmembrane domain 4/5 dimerization interface of the serotonin 5-HT(1A) receptor. Mol. Pharmacol. 82, 448-463, doi: 10.1124/mol.112.079137 (2012).
11. Perreault, M. L., O'Dowd, B. F. & George, S. R. Dopamine receptor homooligomers and heterooligomers in schizophrenia. CNS Neurosci. Ther. 17, 52-57, doi: 10.1111/j.1755-5949.2010.00228.x (2011).
12. Maggio, R. & Millan, M. J. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr. Opin. Pharmacol. 10, 100-107, doi: 10.1016/j.coph.2009.10.001 (2010).
13. Hasbi, A. et al. A peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function in vitro and in vivo: effective selective antagonism. FASEB J. 28, 4806-4820, doi: 10.1096/fj.14-254037 (2014).
14. Borroto-Escuela, D. O. et al. Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. Biochem. Biophys. Res. Commun. 402, 801-807, doi: 10.1016/j.bbrc.2010.10.122 (2010).
15. Rodríguez-Ruiz, M. et al. Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate GlutamateReceptors as Targets to Prevent Neuronal Death in Alzheimer's Disease. Mol. Neurobiol. [Epub ahead of print] (2016).
16. Le Foll, B. & Di Ciano, P. Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction. Eur. Neuropsychopharmacol. 25, 1401-1409, doi: 10.1016/j.euroneuro.2014.08.017 (2014).
17. Groman, S. M. et al. Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making. J. Neurosci. 36, 6732-6741, doi: 10.1523/JNEUROSCI.3253-15.2016 (2016).
18. 3 receptor dimers and tetramers in brain and transfected cells. J. Biol. Chem. 272, 29229-29237, doi: 10.1074/jbc.272.46.29229 (1997).
19. Karpa, K. D., Lin, R., Kabbani, N. & Levenson, R. The dopamine D3 receptor interacts with itself and the truncated D3 splice variant d3nf: D3-D3nf interaction causes mislocalization of D3 receptors. Mol. Pharmacol. 58, 677-683 (2000).
20. Marsango, S., Caltabiano, G., Pou, C., Varela Liste, M. J. & Milligan, G. Analysis of Human Dopamine D3 Receptor Quaternary Structure. J. Biol. Chem. 290, 15146-15162, doi: 10.1074/jbc.M114.630681 (2015).
21. Liste, M. J. et al. The molecular basis of oligomeric organization of the human M3 muscarinic acetylcholine receptor. Mol. Pharmacol. 87, 936-953, doi: 10.1124/mol.114.096925 (2015).
22. Chien, E. Y. et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330, 1091-1095, doi: 10.1126/science.1197410 (2010).
23. Thomas, T., Fang, Y., Yuriev, E. & Chalmers, D. K. Ligand Binding Pathways of Clozapine and Haloperidol in the Dopamine D2 and D3 Receptors. J. Chem. Inf. Model. 56, 308-321, doi: 10.1021/acs.jcim.5b00457 (2016).
24. Godin et al. Revealing protein oligomerization and densities in situ using spatial intensity distribution analysis. Proc. Natl. Acad. Sci USA 108, 7010-7015, doi: 10.1073/pnas.1018658108 (2011).
25. Barbeau, A. et al. Quantification of receptor tyrosine kinase activation and transactivation by G-protein-coupled receptors using spatial intensity distribution analysis (SpIDA). Methods Enzymol. 522, 109-131, doi: 10.1016/B978-0-12-407865-9.00007-8 (2013).
26. Godin, A. G. et al. Spatial Intensity Distribution Analysis reveals abnormal oligomerization of proteins in single cells. Biophys. J. 109, 710-721, doi: 10.1016/j.bpj.2015.06.068 (2015).
27. Pediani, J. D., Ward, R. J., Godin, A. G., Marsango, S. & Milligan, G. Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs. J. Biol. Chem. 291, 13132-13146, doi: 10.1074/jbc.M115.712562 (2016).
28. von Stetten, D., Noirclerc-Savoye, M., Goedhart, J., Gadella, T. W. J. & Royant, A. Structure of a fluorescent protein from Aequorea victoria bearing the obligate-monomer mutation A206K. Acta Crystallogr. F Struct. Biol. Cryst. Commun. 68, 878-882, doi: 10.1107/S1744309112028667 (2012).
29. Ward, R. J., Alvarez-Curto, E. & Milligan, G. Using the Flp-In T-Rex system to regulate GPCR expression. Methods Mol. Biol. 746, 21-37, doi: 10.1007/978-1-61779-126-0-2 (2011).
30. Lesage, A. S. et al. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br. J. Pharmacol. 123, 1655-1665, doi: 10.1038/sj.bjp.0701766 (1998).
31. Gazi, L. et al. Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells. Br. J. Pharmacol. 128, 613-20, doi: 10.1038/sj.bjp.0702849 (1999).
32. Kortagere, S. et al. Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies. Biochem. Pharmacol. 81, 157-163, doi: 10.1016/j.bcp.2010.08.026 (2011).
33. Lane, J. R., Powney, B., Wise, A., Rees, S. & Milligan, G. G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors. J. Pharmacol. Exp. Ther. 325, 319-330, doi: 10.1124/jpet.107.134296 (2008).
34. Ballesteros, J. A. & Weinstein, H. Integrated methods for modelling G-protein coupled receptors. Methods Neurosci. 366-428 (1995).
35. Hern, J. A. et al. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. USA 107, 2693-2698, doi: 10.1073/pnas.0907915107 (2010).
36. 2 muscarinic acetylcholine receptors in live cardiac muscle. J. Mol. Cell Cardiol. 57, 129-136, doi: 10.1016/j.yjmcc.2013.01.009 (2013).
37. Tabor, A. et al. Visualization and ligand-induced modulation of dopamine receptor dimerization at the single molecule level. Sci. Rep. 6, doi: 10.1038/srep33233 (2016).
38. Kasai, R. S. et al. Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. J. Cell Biol. 192, 463-80, doi: 10.1083/jcb.201009128 (2011).
39. Kusumi, A., Tsunoyama, T. A., Hirosawa, K. M., Kasai, R. S. & Fujiwara, T. K. Tracking single molecules at work in living cells. Nat. Chem. Biol. 10, 524-32, doi: 10.1038/nchembio.1558 (2014).
40. Calebiro, D. et al. Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc. Natl. Acad. Sci. USA 110, 743-748, doi: 10.1073/pnas.1205798110 (2013).
41. Ward, R. J., Pediani, J. D., Godin, A. G. & Milligan, G. Regulation of oligomeric organization of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor observed by spatial intensity distribution analysis. J. Biol. Chem. 290, 12844-12857, doi: 10.1074/jbc.M115.644724 (2015).
42. Mishra, A. K. et al. Quaternary structures of opsin in live cells revealed by FRET spectrometry. Biochem J. 473, 3819-3836, doi: 10.1042/BCJ20160422 (2016).
43. Herrick-Davis, K., Grinde, E., Cowan, A. & Mazurkiewicz, J. E. Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. Mol. Pharmacol. 84, 630-642, doi: 10.1124/mol.113.087072 (2013).
44. Milligan, G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharm. 66, 1-7, doi: 10.1124/mol.104.000497 (2004).
45. Milligan, G. G protein-coupled receptor hetero-dimerisation: contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14, doi: 10.1111/j.1476-5381.2009.00169.x (2009).
46. Milligan, G. The prevalence, maintenance and relevance of G protein-coupled receptor oligomerisation. Mol. Pharm. 84, 158-169, doi: 10.1124/mol.113.084780 (2013).
47. Saenz del Burgo, L. & Milligan, G. Heterodimerisation of G protein-coupled receptors: implications for drug design and ligand screening. Expert. Opin. Drug Discov. 5, 461-474, doi: 10.1517/17460441003720467 (2010).
48. Ilien, B. et al. Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. J. Biol. Chem. 284, 19533-19543, doi: 10.1074/jbc.M109.017145 (2009).
49. Wang, M. et al. Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. Mol. Brain 3, 25-34, doi: 10.1186/1756-6606-3-25 (2010).
50. Seeman, P. Schizophrenia and dopamine receptors. Eur. Neuropsychopharmacol. 23, 999-1009, doi: 10.1016/j.euroneuro.2013.06.005 (2013).
51. Eswar, N. et al. Comparative protein structure modeling using Modeller. Curr. Protoc. bioinformatics Chapter 5, doi: 10.1002/0471250953.bi0506s15 (Chapter 5, 5.6.1-5.6.30) (2006).
52. Huang, J., Chen, S., Zhang, J. J. & Huang, X. Y. Crystal structure of oligomeric β1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat. Struct. Mol. Biol. 20, 419-25, doi: 10.1038/nsmb.2504 (2013).
53. Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 30, 455-61, doi: 10.1002/jcc.21334 (2010).
54. Hess, B., Kutzner, C., van der Spoel, D. & Lindahl, E. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. in. J. Chem. Theory Comput. 4, 435-47, doi: 10.1021/ct700301q (2008).
55. Cordomí, A., Caltabiano, G. & Pardo, L. Membrane Protein Simulations Using AMBER Force Field and Berger Lipid Parameters. J. Chem. Theory Comput. 8, 948-958, doi: 10.1021/ct200491c (2012).
56. Humphrey, W., Dalke, A. & Schulten, K. VMD - Visual Molecular Dynamics. J. Mol. Graph. 14(33-38), 27-28, doi: 10.1016/0263-7855(96)00018-5 (1996).